H
Hsu-Ping Kuo
Researcher at University of Texas MD Anderson Cancer Center
Publications - 35
Citations - 2188
Hsu-Ping Kuo is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ibrutinib & Bruton's tyrosine kinase. The author has an hindex of 20, co-authored 35 publications receiving 2010 citations. Previous affiliations of Hsu-Ping Kuo include Stanford University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Jer Yen Yang,Cong S. Zong,Weiya Xia,Hirohito Yamaguchi,Qingqing Ding,Xiaoming Xie,Jingyu Lang,Chien-Chen Lai,Chun Ju Chang,Wei Chien Huang,Hsin Huang,Hsu-Ping Kuo,Hsu-Ping Kuo,Dung Fang Lee,Dung Fang Lee,Long Yuan Li,Long Yuan Li,Huang-Chun Lien,Xiaoyun Cheng,Xiaoyun Cheng,King-Jen Chang,Chwan-Deng Hsiao,Fuu Jen Tsai,Chang Hai Tsai,Chang Hai Tsai,Aysegul A. Sahin,William J. Muller,Gordon B. Mills,Dihua Yu,Gabriel N. Hortobagyi,Mien Chie Hung +30 more
TL;DR: This study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS–ERK and MDM2 and downregulates Forkhead box O 3a by directly interacting with and phosphorylating FOXO 3a at Ser 294, Ser 344 and Ser 425.
Journal ArticleDOI
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma
TL;DR: The data suggest that the combination of intratumoral injection of DCs and conformal radiotherapy is safe and can induce tumor-specific and innate immunity.
Journal ArticleDOI
Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
Qingqing Ding,Longfei Huo,Jer Yen Yang,Jer Yen Yang,Weiya Xia,Yongkun Wei,Yong Liao,Chun Ju Chang,Yan Yang,Chien-Chen Lai,Dung Fang Lee,Dung Fang Lee,Chia Jui Yen,Yun Ju Rita Chen,Jung Mao Hsu,Hsu-Ping Kuo,Hsu-Ping Kuo,Chun Yi Lin,Fuu Jen Tsai,Long Yuan Li,Chang Hai Tsai,Chang Hai Tsai,Mien Chie Hung +22 more
TL;DR: A novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance is unraveled and provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.
Journal ArticleDOI
Cancer-specific activation of the survivin promoter and its potential use in gene therapy
Jin-Shing Chen,Jaw Ching Liu,Lei Shen,Lei Shen,Kung Ming Rau,Kung Ming Rau,Hsu-Ping Kuo,Yan Michael Li,Daren Shi,Lee Yc,King-Jen Chang,Mien Chie Hung +11 more
TL;DR: The results indicate that the survivin promoter is a cancer-specific promoter for various cancers and that it may be useful in cancer gene therapy.
Journal ArticleDOI
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis
Qingqing Ding,Chun Ju Chang,Xiaoming Xie,Weiya Xia,Jer Yen Yang,Jer Yen Yang,Shao Chun Wang,Yan Wang,Jiahong Xia,Libo Chen,Changchung Cai,Huabin Li,Chia Jui Yen,Hsu-Ping Kuo,Hsu-Ping Kuo,Dung Fang Lee,Dung Fang Lee,Jingyu Lang,Longfei Huo,Xiaoyun Cheng,Xiaoyun Cheng,Yun Ju Chen,Chia Wei Li,Long Bin Jeng,Jennifer L. Hsu,Long Yuan Li,Alai Tan,Steven A. Curley,Lee M. Ellis,Raymond N. DuBois,Mien Chie Hung +30 more
TL;DR: Key factors and mechanisms involved in colorectal cancer liver metastasis are elucidated, which could be potential targets for diagnosis and treatment.